Physician profile
Libby K Sisson
NPI 1346770310
$742.31
in general payments reported to CMS, 2019-2025
21 companies · $380 in 2025
The $380 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $21.71 · 2022: $32.51 · 2023: $73.66 · 2024: $234 · 2025: $380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $688.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $688.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $106.43 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $94.43 | 2023-2025 | |
| Lilly USA, LLC | $91.02 | 2022-2024 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $54.30 | 2024-2025 | |
| Gilead Sciences, INC. | $49.80 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.68 | 2024 | Jardiance |
| Glaxosmithkline, LLC. | $34.56 | 2025 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.98 | 2023-2025 | Xifaxan |
| Dexcom, INC. | $29.09 | 2025 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $26.21 | 2025 | Auvelity |
| Inspire Medical Systems, INC. | $24.38 | 2025 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $21.71 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $21.06 | 2025 | Farxiga |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.76 | 2025 | Caplyta |
| Exact Sciences Corporation | $19.58 | 2025 | Cologuard Collection Kit |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $16.27 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.78 | 2023 | |
| Corium, LLC | $14.45 | 2024 | Azstarys |
| Qol Medical, LLC | $14.08 | 2023 | Sucraid |
| Teva Pharmaceuticals USA, INC. | $14.07 | 2024 | Austedo Xr |
| Phathom Pharmaceuticals, INC. | $8.67 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Libby Sisson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.